These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells. Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643 [TBL] [Abstract][Full Text] [Related]
7. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Hanlon DJ; Aldo PB; Devine L; Alvero AB; Engberg AK; Edelson R; Mor G Am J Reprod Immunol; 2011 Jun; 65(6):597-609. PubMed ID: 21241402 [TBL] [Abstract][Full Text] [Related]
8. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy. Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z Small; 2017 Oct; 13(40):. PubMed ID: 28861943 [TBL] [Abstract][Full Text] [Related]
9. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses. Li H; Shao S; Cai J; Burner D; Lu L; Chen Q; Minev B; Ma W Immunology; 2017 Nov; 152(3):462-471. PubMed ID: 28664991 [TBL] [Abstract][Full Text] [Related]
10. Artificial antigen-presenting cells for use in adoptive immunotherapy. Turtle CJ; Riddell SR Cancer J; 2010; 16(4):374-81. PubMed ID: 20693850 [TBL] [Abstract][Full Text] [Related]
11. Nanoscale artificial antigen presenting cells for cancer immunotherapy. Rhodes KR; Green JJ Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074 [TBL] [Abstract][Full Text] [Related]
12. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. Zupančič E; Curato C; Paisana M; Rodrigues C; Porat Z; Viana AS; Afonso CAM; Pinto J; Gaspar R; Moreira JN; Satchi-Fainaro R; Jung S; Florindo HF J Control Release; 2017 Jul; 258():182-195. PubMed ID: 28511928 [TBL] [Abstract][Full Text] [Related]
13. Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation. Hickey JW; Vicente FP; Howard GP; Mao HQ; Schneck JP Nano Lett; 2017 Nov; 17(11):7045-7054. PubMed ID: 28994285 [TBL] [Abstract][Full Text] [Related]
14. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses. Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669 [TBL] [Abstract][Full Text] [Related]
15. Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model. Zhang L; Wang L; Shahzad KA; Xu T; Wan X; Pei W; Shen C Cancer Immunol Immunother; 2017 Sep; 66(9):1229-1241. PubMed ID: 28501941 [TBL] [Abstract][Full Text] [Related]
16. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Eggermont LJ; Paulis LE; Tel J; Figdor CG Trends Biotechnol; 2014 Sep; 32(9):456-65. PubMed ID: 24998519 [TBL] [Abstract][Full Text] [Related]
17. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Waeckerle-Men Y; Gander B; Groettrup M Methods Mol Med; 2005; 109():35-46. PubMed ID: 15585911 [TBL] [Abstract][Full Text] [Related]
18. Nanotechnology-Based Cancer Vaccine. Alshamsan A Methods Mol Biol; 2017; 1530():257-270. PubMed ID: 28150207 [TBL] [Abstract][Full Text] [Related]
19. HLA-Class II Artificial Antigen Presenting Cells in CD4 Couture A; Garnier A; Docagne F; Boyer O; Vivien D; Le-Mauff B; Latouche JB; Toutirais O Front Immunol; 2019; 10():1081. PubMed ID: 31156634 [TBL] [Abstract][Full Text] [Related]
20. Biomimetic dendritic polymeric microspheres induce enhanced T cell activation and expansion for adoptive tumor immunotherapy. Yang H; Sun L; Chen R; Xiong Z; Yu W; Liu Z; Chen H Biomaterials; 2023 May; 296():122048. PubMed ID: 36842237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]